DPP-4 inhibitors are considered weight neutral and have generally been shown to improve other cardiovascular risk factors, including low-density lipoprotein, high-density lipoprotein, and blood pressure.
Linagliptin is most effective in the inhibition of enzyme as compared to other DPP-4 inhibitors.
Answered2023-12-25 04:09:27
Let others know if this answer was helpful